Advanced Peer Research
Peers Analysis
| Company |
Price |
P/E |
EPS |
Marcap |
1 Yr performance |
52W Low - High |
52W Low - High range |
Valuation |
| Amgen Inc. |
$
265.52 |
25.75 |
10.31 |
150,776 |
-6.05 % |
214.27 - 286.88 |
|
Overvalued |
| AstraZeneca PLC |
$
9,900.00 |
6,971.83 |
1.42 |
15,345,000 |
-10.41 % |
101.80 - 12,294.00 |
|
Undervalued |
| Bayer AG |
€
30.56 |
8.00 |
3.82 |
30,023 |
-45.18 % |
30.56 - 62.49 |
|
Undervalued |
| Biogen Inc. |
$
227.41 |
29.69 |
7.66 |
34,239 |
-22.09 % |
222.59 - 318.06 |
|
Overvalued |
| Gilead Sciences Inc. |
$
74.51 |
53.22 |
1.40 |
93,138 |
-12.56 % |
73.27 - 89.47 |
|
Overvalued |
| GlaxoSmithKline plc |
£
35.64 |
15.56 |
2.29 |
89,813 |
5.57 % |
33.50 - 38.32 |
|
Undervalued |
| Grifols S.A. |
€
12.89 |
19.83 |
0.65 |
5,442 |
26.62 % |
8.41 - 14.35 |
|
Undervalued |
| Johnson & Johnson Inc. |
$
151.63 |
17.99 |
8.43 |
398,787 |
-14.49 % |
145.60 - 180.25 |
|
Undervalued |
